AGIOS PHARMACEUTICALS, INC. Decrease in Restricted Cash
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Decrease in Restricted Cash of $571.00 thousand for the 12-month period ending 2014-12-31, per its 10-K filed 2017-02-16.
Discontinued › Notes
us-gaap:DecreaseInRestrictedCash · last filed 2017-02-16
- AGIOS PHARMACEUTICALS, INC. decrease in restricted cash for the quarter ending 2014-12-31 was $0.00.
- AGIOS PHARMACEUTICALS, INC. decrease in restricted cash for fiscal 2014 was $571.00K.
| Period end | Decrease in Restricted Cash 3 month | Decrease in Restricted Cash 9 month | Decrease in Restricted Cash 12 month |
|---|---|---|---|
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-16 | $571.00K 10-K · filed 2017-02-16 | |
| 2014-09-30 | $571.00K 10-Q · filed 2015-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |